Jenny Zilberberg

Jenny Zilberberg is a Sr. Principal Scientist at Imvax, Inc. since 2020. Prior to that, they were a Group Leader at the Center for Discovery and Innovation from 2018 to 2020, where they led a cross-functional and multi-institutional research team to develop ex vivo culture platforms and complex multicellular assays for screening patient-specific treatment options. Jenny also assessed the application of the technology for evaluation of novel cellular immunotherapies and identification of targetable biomarkers in treatment-resistant myeloma. Before that, they were an Assistant Scientist at Hackensack University Medical Center from 2004 to 2018, where they worked on unraveling the immunobiology of bone marrow transplantation and the development of novel immunotherapeutic approaches for the treatment of hematological cancers and graft-versus-host disease. Jenny also carried out in vivo and in vitro evaluation of proteasome inhibitors ONX 0914 and PR-825 (Onyx Pharmaceuticals Inc. sponsored project).

Jenny Zilberberg's education history includes a Doctor of Philosophy (Ph.D.) in Bioengineering from Penn State University from 1998 to 2001, a Master of Science (M.S.) in Bioengineering from Penn State University from 1996 to 1998, a Bachelor's degree in Chemical Engineering from Universidad Simón Bolívar from 1991 to 1996, and a high school diploma from Moral y Luces.